Health Canada Finds No Link Between Winnipeg Plasma Donor Deaths and Donation Process

Health Canada has concluded its assessment into the deaths of two paid plasma donors in Winnipeg, determining that neither fatality was linked to the donation process or equipment at Grifols plasma collection centers.

The federal health regulator announced Friday that after examining the circumstances surrounding the deaths, which occurred in October 2025 and January 2026 at Grifols facilities on Taylor Avenue and Innovation Drive respectively, investigators found no evidence of machine malfunction. "The equipment performed as expected," said Health Canada spokesperson Mark Johnson, noting assessments reviewed timing, cause of death, medical history, and any incidents during collection.

Both deaths, including that of 22-year-old international student Rodiyat Alabede in October 2025, were reported as adverse fatal reactions after plasma donation appointments. Specific causes of death remain under review by Manitoba's chief medical examiner.

Following the incidents, Health Canada imposed new requirements on all 16 licensed Grifols collection centers nationwide, citing recurring deficiencies. The conditions include reducing donor appointments, reassessing training needs for staff, and enhanced donor file reviews. However, the Grifols centre on Innovation Drive was not subject to these new requirements due to operating under a separate licence and quality management system.

Both affected sites were inspected, with several non-compliance issues identified, although specifics have not been released because investigations are ongoing. Health Canada stated that such fatal reactions to plasma donations are rare, and reporting protocols between federal and provincial authorities are under review.

The new regulatory conditions will remain in effect until Grifols demonstrates sustained compliance with federal blood collection standards. Manitoba's health minister and provincial chief medical examiner have not yet commented on the findings.

COMMENTS (0)

Sign in to join the conversation

LOGIN TO COMMENT